Kymera Therapeutics (KYMR) Assets Average (2020 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Assets Average of $1.7 billion for Q1 2026, up 79.92% year-over-year from $948.2 million in Q1 2025, and up 19.93% quarter-over-quarter from $1.4 billion in Q4 2025.
Kymera Therapeutics (KYMR) Assets Average (2020 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Assets Average for 7 consecutive years, with $1.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 79.92% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $1.7 billion (up 79.92% YoY), while the FY2025 annual figure was $1.4 billion, up 75.11% from the prior year.
- Assets Average improved to $1.7 billion in Q1 2026 per KYMR's latest filing, from $1.4 billion in the prior quarter.
- Across five years, Assets Average topped out at $1.7 billion in Q1 2026 and bottomed at $543.2 million in Q2 2022.
- Historically, Assets Average has averaged $846.5 million across 5 years, with a median of $722.0 million in 2024.
- Annual changes were most pronounced in 2023 — Assets Average declined 9.14% — and 2026, when it jumped 79.92%.
- Kymera Therapeutics' Assets Average stood at $620.8 million in 2022, then decreased by 9.14% to $564.1 million in 2023, then soared by 78.42% to $1.0 billion in 2024, then soared by 41.33% to $1.4 billion in 2025, then rose by 19.93% to $1.7 billion in 2026.
- Business Quant data shows KYMR's Assets Average at $1.7 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 1.66 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Bn |
| Mar 31, 2026 | 1.71 Bn |
| Dec 31, 2025 | 1.42 Bn |
| Sep 30, 2025 | 1.12 Bn |
| Jun 30, 2025 | 1.02 Bn |
| Mar 31, 2025 | 948.17 Mn |
| Dec 31, 2024 | 1.01 Bn |
| Sep 30, 2024 | 930.43 Mn |
| Jun 30, 2024 | 847.14 Mn |
| Mar 31, 2024 | 722.01 Mn |
| Dec 31, 2023 | 564.07 Mn |
| Sep 30, 2023 | 567.16 Mn |
| Jun 30, 2023 | 597.93 Mn |
| Mar 31, 2023 | 608.52 Mn |
| Dec 31, 2022 | 620.80 Mn |
| Sep 30, 2022 | 580.95 Mn |
| Jun 30, 2022 | 543.24 Mn |
| Mar 31, 2022 | 584.48 Mn |
| Dec 31, 2021 | 624.18 Mn |
| Sep 30, 2021 | 538.42 Mn |